Home  »  Companies   »  Ginkgo Bioworks Holdings Inc. (DNA) Stock Sees a-1...

Ginkgo Bioworks Holdings Inc. (DNA) Stock Sees a-1.50 Decrease

In the past week, DNA stock has gone up by 4.80%, with a monthly decline of -24.28% and a quarterly plunge of -24.71%. The volatility ratio for the week is 10.27%, and the volatility levels for the last 30 days are 8.59% for Ginkgo Bioworks Holdings Inc. The simple moving average for the last 20 days is -10.58% for DNA stock, with a simple moving average of -45.94% for the last 200 days.

Is It Worth Investing in Ginkgo Bioworks Holdings Inc. (NYSE: DNA) Right Now?

Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".

Sponsored

The average price recommended by analysts for Ginkgo Bioworks Holdings Inc. (DNA) is $4.64, which is $2.28 above the current market price. The public float for DNA is 1.17B and currently, short sellers hold a 12.50% of that float. On March 16, 2023, DNA’s average trading volume was 21.52M shares.

DNA) stock’s latest price update

Ginkgo Bioworks Holdings Inc. (NYSE: DNA)’s stock price has decreased by -1.50 compared to its previous closing price of 1.33. However, the company has seen a gain of 4.80% in its stock price over the last five trading days. Barron’s reported on 10/06/21 that Ginkgo Bioworks Stock Sinks on Short Seller Report

Analysts’ Opinion of DNA

In the past week, DNA stock has gone up by 4.80%, with a monthly decline of -24.28% and a quarterly plunge of -24.71%. The volatility ratio for the week is 10.27%, and the volatility levels for the last 30 days are 8.59% for Ginkgo Bioworks Holdings Inc. The simple moving average for the last 20 days is -10.58% for DNA stock, with a simple moving average of -45.94% for the last 200 days.

Analysts’ Opinion of DNA

Many brokerage firms have already submitted their reports for DNA stocks, with Berenberg repeating the rating for DNA by listing it as a “Buy.” The predicted price for DNA in the upcoming period, according to Berenberg is $6 based on the research report published on November 29th of the previous year 2022.

Morgan Stanley, on the other hand, stated in their research note that they expect to see DNA reach a price target of $5. The rating they have provided for DNA stocks is “Equal-Weight” according to the report published on October 04th, 2022.

BofA Securities gave a rating of “Underperform” to DNA, setting the target price at $3 in the report published on May 18th of the previous year.

DNA Trading at -21.13% from the 50-Day Moving Average

After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.32% of loss for the given period.

Volatility was left at 8.59%, however, over the last 30 days, the volatility rate increased by 10.27%, as shares sank -28.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.04% lower at present.

During the last 5 trading sessions, DNA rose by +3.60%, which changed the moving average for the period of 200-days by -59.66% in comparison to the 20-day moving average, which settled at $1.4388. In addition, Ginkgo Bioworks Holdings Inc. saw -22.49% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at DNA starting from Fallon Marie E., who sold 7,326 shares at the price of $1.33 back on Mar 02. After this action, Fallon Marie E. now owns 164,334 shares of Ginkgo Bioworks Holdings Inc., valued at $9,736 using the latest closing price.

Kelly Jason R sale 100,000 shares at $1.39 during a trade that took place back on Mar 01, which means that Kelly Jason R is holding 12,594,680 shares at $139,400 based on the most recent closing price.

Stock Fundamentals for DNA

Current profitability levels for the company are sitting at:

  • -462.41 for the present operating margin
  • +57.25 for the gross margin

The net margin for Ginkgo Bioworks Holdings Inc. stands at -440.63. Equity return is now at value -195.60, with -148.20 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 8.38.

Conclusion

To wrap up, the performance of Ginkgo Bioworks Holdings Inc. (DNA) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.